To assess the safety and efficacy of ibuprofen in reducing the incidence and severity of bronchopulmonary dysplasia (BPD) in preterm infants.
Since its original description by Northway et al., 1 bronchopulmonary dysplasia (BPD) or chronic lung disease has remained a significant cause of morbidity and mortality in preterm infants. The etiology and pathogenesis of BPD appear to be multifactorial. The principal risk factors are the degree of prematurity, severity of respiratory distress syndrome, duration and intensity of oxygen therapy, and mechanical ventilation. Other contributory factors are inflammation, pulmonary air leak, patent ductus arteriosus (PDA), fluid overload, pulmonary infection including Ureaplasma urealyticum, antioxidant system immaturity, vitamin A deficiency, and possibly genetic predisposition. The extent of the contribution of each of these factors has been difficult to determine. 2 Preterm infants at risk for developing BPD show an enhanced inflammatory reaction in the lungs and an associated increase in pulmonary microvascular permeability. 3 The known actions of corticosteroid treatment are directed to decrease inflammatory cell recruitment and diminish the production and release of mediators of inflammation. 4 However, it is known that steroid treatment in chronic lung disease is associated with many adverse side effects. 2 Ibuprofen (2-4-isobutyl phenyl propionic acid), a cyclooxygenase inhibitor and a nonsteroidal anti-inflammatory drug, is widely used as an antipyretic and also as a long-term treatment in connective tissue and autoimmune disorders in children and adults. The anti-inflammatory effects of ibuprofen have been extensively studied in vitro and in animal models. [5] [6] [7] The pharmacokinetics of ibuprofen have been studied in the pediatric population and in preterm infants. 8 -10 Ibuprofen has been used for the closure of PDA without altering cerebral hemodynamics and oxygenation in preterm infants. 11, 12 Ibuprofen has also been used in cystic fibrosis at doses that produce a plasma concentration of Ͼ50 g/ml to inhibit neutrophil activation and migration. 13 
Objectives
The primary objective of this study was to assess the efficacy and safety of ibuprofen in reducing the incidence and severity of BPD. We pro-
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posed a hypothesis that ibuprofen would prevent or reduce the severity of BPD by attenuating the inflammation. We further hypothesized that ibuprofen would also reduce the need for steroids, facilitate weaning from mechanical ventilation and oxygen, and shorten the length of hospital stay.
METHODS
Between July of 1997 and June of 1998 we studied 18 preterm infants of Յ28 weeks' gestation in a level III neonatal intensive care unit. Birth weight ranged from 480 to 1180 gm. Infants between 7 and 14 days of postnatal age requiring ventilatory support (with FIO 2 of Ͼ0.3 and a ventilator rate of Ն10 despite weaning trial) were eligible for the study. The exclusion criteria were major congenital anomalies, bleeding diathesis, thrombocytopenia (a platelet count of Ͻ70,000), impending or established renal failure (serum creatinine of Ͼ1.2 mg/dl and/or urine output of Ͻ1 ml/kg per hour in 12 hours), congestive heart failure, suspected or proven necrotizing enterocolitis (NEC), intestinal hemorrhage or perforation, intraventricular hemorrhage (IVH) of severe degree (grade 3 and 4), moribund clinical condition, and previous treatment with ibuprofen for PDA closure (as part of another concurrent study in our neonatal intensive care unit). All parents of eligible infants were approached. Nine infants whose parents agreed to participate were enrolled after obtaining informed consent. Ibuprofen was administered to these infants. After the enrollment of study infants, an equal number of infants were selected for the control group matching for gestation, sex, race, use of prenatal steroids, postnatal age, and severity of respiratory illness.
The parenteral ibuprofen preparation was obtained as ibuprofen lysine from Merckle Laboratories (Ulm, Germany). Based on an earlier study of ibuprofen for PDA in preterm infants, 11 a loading dose of 10 mg/kg of ibuprofen followed by 5 mg/kg per dose at 12-hour intervals was administered. The route of administration was intravenous or oral depending on tolerance of enteral feeds. Ibuprofen was continued until 28 days of life or until the infants were weaned from the ventilator and oxygen (whichever occurred earlier).
Daily fluid requirements and the use of bronchodilators and diuretics for BPD were at the discretion of attending physicians. Steroids were given only when specific guidelines were met, including an oxygen requirement of Ͼ30% to maintain oxygen saturation at 90% to 95% for Ͼ48 hours at or after 2 weeks of age. Dexamethasone was given for 12 days with an initial dose of 0.5 mg/kg per day, and the dose was halved every 3 days. The infants were monitored for any side effects of ibuprofen such as renal, hematologic, and gastrointestinal complications. Cranial ultrasounds and eye examinations were performed according to nursery protocols.
BPD was defined as oxygen dependence at 36 weeks postconceptional age.
14 Accepted classifications were used for the grading of IVH, NEC, and retinopathy of prematurity. [15] [16] [17] A daily ventilatory efficiency index (VEI) was calculated for all of the infants using the following formula: ([PaCO 2 ϫ peak inspiratory pressure ϫ ventilator rate]/ [1000]) 18 before and during the study.
Plasma ibuprofen levels were measured in a subset of four patients at 0 and 3 hours after the first intravenous dose and randomly in another infant. The plasma samples were analyzed using gas chromatography and mass spectrometry. The coefficient variation for this method was 5%.
All infants were followed until discharge from the hospital. Oxygen dependence at 36 weeks postconceptional age, tolerance of enteral feeds, steroid usage, length of stay in the hospital, and frequency of potential complications of ibuprofen were compared between the two groups. The study was approved by the Human Investigation Committee of Wayne State University.
Statistics
The study data were analyzed using Statistical Package for Social Sciences (version 9.0) (SPSS, Inc., Chicago, IL). Both descriptive (univariate) and inferential statistical procedures were used to examine the two groups. Categorical (nominal) or ordinal (ranked) data were analyzed using Fisher's exact -squared test to examine differences in proportions and possible associations. Differences were considered to be significant at a p value of Ͻ0.05 (two-sided). Data scaled continuously (internal/ratio) and linear in nature were compared using the independent sample t-test. Where the assumption of homogeneity of variance was violated, the nonparametric MannWhitney U test and Z score were interpreted for significance.
RESULTS
There were no significant differences between the two groups with regard to sex, racial distribution, prenatal steroid use, birth weight, Apgar scores, and oxygen and ventilator requirements at the time of entry into the study (Table 1) . Plasma levels at 3 hours after the initial intravenous dose of ibuprofen ranged from 10.3 to 36 mg/liter ( Table 2) .
The total number of ibuprofen doses ranged from 8 to 41. The study drug was withdrawn in one infant after 8 days (15 doses) of treatment due to gastrointestinal hemorrhage that occurred 6 hours after the last dose. The plasma ibuprofen level at the time of complication was 7.3 mg/liter. The study drug was discontinued after eight doses in another infant, because the baby was transferred to another hospital for reasons unrelated to our study.
The outcome variables are presented in Table 3 . Renal parameters (blood urea nitrogen, serum creatinine) and urine output were comparable in both groups. In one infant, the creatinine level was 1.7 mg/dl at 4 days after the last dose of ibuprofen. This normalized in the next 3 days. None of the infants developed NEC during the study period. However, one infant in the ibuprofen group developed NEC 3 weeks after completion of the study and required surgery. One infant in each group had grade III IVH, and two infants in the ibuprofen group and one in the control group had grade II IVH (not significant). There were no significant differences in the incidence of infections and retinopathy of prematurity between the groups.
Eight infants in each group met the criteria for BPD (not significant), and four infants in each group required home oxygen therapy. The total number of ventilator days was found to be less in the study group (34 Ϯ 25 days) compared with the control group (47 Ϯ 18 days), although this difference was not significant ( p ϭ 0.2). Oxygen requirement during and at the end of the study was not significantly different between the two groups. The VEI was also not significantly different between the groups at the end of 1 week (15.8 Ϯ 7.7 for the ibuprofen group versus 16.2 Ϯ 5.5 for the control group). The length of hospital stay was found to be less in the ibuprofen group (91 days) compared with the control group (97 days), but this also was not significant. Infants in the ibuprofen group attained the full enteral goal earlier (14 Ϯ 6 days) than controls (26 Ϯ 13 days). This difference was statistically significant ( p ϭ 0.04). Five infants in each group received steroids. Infants who received steroids in the ibuprofen group were weaned from the ventilator earlier (27 days) than infants in the control group that were treated with steroids (58 days). This difference reached statistical significance ( p ϭ 0.04). However, there was no difference in the incidence of BPD between the two groups with the addition of steroids.
DISCUSSION
This study describes a novel application of ibuprofen for prevention and/or treatment of BPD. In this phase I study, we observed a trend toward a lesser number of ventilator and hospital days.
The pathophysiology of BPD is complex and multifactorial. Prematurity, severity of respiratory distress syndrome, duration and intensity of oxygen therapy, and mechanical ventilation appear to be the most important determinants. Inflammation is also an important contributor in the development of BPD. There is a 20-fold increase in cell number in tracheal aspirates from babies who progress to develop BPD compared with those with uneventful recovery. 19 Leukotrienes are potent airway constrictors and may play a significant role in the development of BPD. 20 Varvarigou et al. 11 demonstrated a reduction in plasma prostaglandin levels, lower daily mean airway pressures, a better oxygenation index, and fewer days of ventilation and hospitalization in infants receiving ibuprofen for early closure of PDA. Whether this improvement was secondary to the closure of PDA in the study group or was an independent response is not known.
The inhibitory effects on neutrophil activation and migration generally occur at ibuprofen plasma concentrations of Ͼ50 mg/ liter. 13 Although we aimed for plasma ibuprofen levels of Ն50 mg/ liter, we could only achieve a maximum of 36 mg/liter at 3 hours after the initial dose. These levels are much lower than those reported by Aranda et al. 8 (150.5 Ϯ 45.5 at 3 hours after the administration of a similar dose). The plasma half-life of ibuprofen is age-dependent and ranges from 30.5 Ϯ 4.2 hours at 0 to 3 hours of age to 1.6 Ϯ 0.7 hours at 3 months to 10 years. 8, 10 This may suggest that the pharmacokinetics of ibuprofen could be different in the late neonatal period compared with the first week of life. Lower levels in our infants could be a reflection of increased maturity as well as of metabolism by the liver.
The infants receiving ibuprofen tolerated feeds better and achieved the full enteral goal sooner than controls. Varvarigou et al. 11 also reported a similar observation in their study of ibuprofen use for ‫ء‬The infant had a transient rise in serum creatinine at 4 days after the last dose. ‫ءء‬The levels were drawn when the infant developed gastrointestinal hemorrhage.
PDA closure. Study infants, despite requiring slightly higher inspired oxygen at entry, showed a trend toward a greater decline in VEI at the end of 1 week. However, there was no difference in the incidence of BPD between the two groups. With the addition of steroids, the duration of mechanical ventilation was shorter in the ibuprofen group compared with controls. The lack of an anticipated respiratory response to ibuprofen could be due to the following reasons: The sample size was small, the dosage and duration of treatment were probably inadequate, and the cyclooxygenase pathway may not be as important as the lipooxygenase pathway in the pathophysiology of BPD. The infants were enrolled after the first week of life, by which time the inflammation and damage could have well set in. Most notably, the infants in both groups were extremely premature and small.
The infant with gastrointestinal hemorrhage in the study was also receiving steroids and aminophylline at the same time. Another infant required surgery for NEC, which developed 21 days after completion of the study. Ibuprofen might not be the cause of NEC in this infant because of the prolonged time period between its last dose and the development of NEC. A third infant was noted to have serum creatinine value of 1.7 mg/dl at 4 days after the last dose of the study drug; this infant was also on vancomycin for presumed sepsis. The vancomycin levels were therapeutic (peak level of 12.1 g/ml and trough levels of 9.5 and 6.8 g/ml). The renal parameters were subsequently normal after 3 days. This infant was not on steroids. Although three of nine infants in the study group developed complications, it is difficult to attribute these side effects to ibuprofen alone for the reasons stated above.
The limitation of the study is that it is not a randomized control trial. However, it was designed as a small phase I study. Although the controls were selected retrospectively, they were well matched and the follow-up was complete. Exclusion of the infants with PDA allowed us to look at the independent effect of ibuprofen on respiratory outcome.
Whether early and prolonged administration of ibuprofen will benefit the infants by preventing PDA, BPD, and other outcomes needs to be examined in a larger sample size. In addition, the exact dosage, timing, route of administration, and duration of ibuprofen in neonates needs to be determined. The pharmacokinetics of ibuprofen in preterm infants need further investigation as well. Although this study is the first to report the potential use of ibuprofen to reduce the incidence and/or severity of BPD in preterm infants, future studies are necessary to determine the risk/benefit ratio.
